Crisugabalin provides significant improvement in average daily pain score and shows promise as a postherpetic neuralgia treatment.

Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and ...

Averitas Pharma, the US subsidiary of Grünenthal, has completed patient recruitment for the Phase III AV001 clinical study, ...

Crisugabalin at 40 mg/d or 80 m/d for postherpetic neuralgia treatment led to statistically significant improvement in average daily pain scores. Crisugabalin as a treatment for postherpetic ...

Many Brits might unknowingly be walking a knife’s edge with their health, as an expert warned if left untreated, the disease ...

Longer-term complications include visual disturbances and postherpetic neuralgia (PHN), which is ... 50% of patients gain 50% relief of pain). With the older adult population steadily growing ...

The Phase III trial AV001 aims to evaluate QUTENZA in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures ...

Many Brits could be unknowingly teetering on the brink of serious health issues, as a leading expert warns that if left ...

When Grünenthal acquired the US-rights for Qutenza ® in 2018, the US-label comprised the treatment of neuropathic pain associated with postherpetic neuralgia. Since then, Grünenthal re-launched ...